Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Spyre Therapeutics, Inc.

Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.

Metric
Company Name	Spyre Therapeutics, Inc.
Symbol	SYRE
MSH ID	COM:SPYRE
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	30
Website	spyre.com
LinkedIn	spyre-therapeutics
Founders

Metric
Market Cap	1.42B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	886K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-78K
EBITDA	69.45M
Operating Income	-242.30M
Net Income	-338.79M
EPS	-49.12
Diluted EPS	-49.12
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.20
Operating Profit Margin	-149.88
EBITDA Margin	78.38
Net Profit Margin	-178.48
Return on Equity	12.51
Return on Assets	-0.43
Return on Capital Employed	-0.38

SYRE

COM:SPYRE

Spyre Group

Last Close

27.00

22/11 21:00

Market Cap

1.42B

Beta: -

Volume Today

793.23K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.71
P/B Ratio	3.16
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.60K
EV Multiple	47.20

Metric
Days Sales Outstanding
Days Payables Outstanding	339.25
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle	-339.25
Asset Turnover	0.00

Metric
Operating Cash Flow	-99.91M
Free Cash Flow	-99.91M
Cash Flow to Debt
Operating Cash Flow/Sales	-64.06
Free Cash Flow Yield	-0.07

Metric
Cash & Equivalents	188.89M
Accounts Receivable	375K
Inventory
Goodwill
Debt to Capitalization	0.62
Debt to Assets	0.25
Current Ratio	10.68
Quick Ratio	19.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	28.98
R&D to Revenue	101.02
SG&A to Revenue	45.09